Sanwa Kagaku Kenkyusho Co., Ltd.

Toshinao Usui

Masayasu Kurono

Yasuaki Kondo

Kiichi Sawai

Kenji Miura

Takuji Yamaguchi

Ryoichi Unno

Masato Fukushima

Kuniharu Mizuno

Akira Matsubara

Kyoichi Asano

Noriaki Kato

Naofumi Terada

Takuji Kakigami

Hiroshi Ozawa

Yutaka Baba

Yoshiro Ozeki

Katsura Tsukamoto

Hiromoto Kimura

Tsunemasa Suzuki

Nobuyuki Itoh

Yasuo Suzuki

Takashi Ito

Takahiko Mitani

Akira Hasegawa

Takahito Jomori

Kunihiro Sumoto

Seiji Miyano

Shoji Yokochi

Mitsuru Oka

Akira Tashita

Tomoo Suzuki

Noboru Kuboyama

Noboru Tomiya

Noriyuki Iwata

Motohide Hayashi

Nobuyuki Ito

Shinichi Ikeda

Nobuyuki Asaeda

Yoshiro Ishiwatari

Hitoshi Hamashima

Takao Igami

Kenji Hamase

Yukiya Tanaka

Shigeyoshi Nakamura

There are described sulfated and phosphated saccharide erivatives of the Formula ##STR1## wherein R.sub.1 is hydrogen atom or a residue of sulfate, phosphate or L-fucose; R.sub.2, R.sub.3 and R.sub.4 are hydrogen atom or a residue of sulfate or phosphate, respectively; 1 is an integer of 0 or 1;

Sulfated and phosphated saccharide derivatives, process for the

There are disclosed a 1-azabicyclo[3.3.0]octan derivative of the formula ##STR1## wherein n is an integer of 1-5; and Ar is an aromatic residue. a pharmacologically acceptable salt of the compound, a process for the preparation of the compound and salt as well as use thereof as hypermotility agents.

1-azabicyclo[3.3.0]octan derivative, salt thereof, process for the

There are disclosed a benzopyrancarboxamide derivative of the formula ##STR1## wherein R.sup.1 is hydrogen atom or a lower alkyl group; R.sup.2 is hydrogen atom, a lower alkyl group, halogen atom, an amino radical or an acylamino group; R.sup.3 is hydrogen atom, a lower alkyl group, a lower alkoxy group or halogen atom; dotted line is a possible double bond; and n is an integer of 1-5, and a pharmacologically acceptable salt of the compound, a process for the preparation of the compound and salt as well as use thereof.

Benzopyrancarboxamide derivatives, salts thereof, process for the

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,

Hydantoin derivatives for treating complications of diabetes

There are disclosed a benzo[b]furancarboxamide derivative of the formula ##STR1## wherein R.sup.a, R.sup.b, R.sup.c and R.sup.d are a hydrogen atom or lower alkyl group, respectively; R.sup.e is a hydrogen atom, amino radical, lower alkylamino group or acylamino group; X is a hydrogen atom or halogen atom; and n is an integer of 1-5, and including racemic compounds and stereo-isomers thereof, a salt of the compounds, a process for the preparation of the compounds and salts as well as use thereof for improving hypermotility.

Benzo[B]Furancarboxamide derivatives, process for the preparation of

A process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives of the formula ##STR1## wherein X and Y are hydrogen atom, halogen atom or alkyl group, and R.sub.1 is hydrogen atom or alkyl group, intermediates thereof, as well as a process for the preparation of the intermediates.

Process for the preparation of optically active

The invention relates to a hydantoin derivative, salt thereof, process for the preparation thereof, and medicine containing the derivative. The derivative is represented by the formula ##STR1## wherein M is --CONH--NHR.sup.1 group, --CONH--OR.sup.2 group, ##STR2## in which R.sup.1 is hydrogen atom, an alkyl group, an alkenyl group, a phenyl radical, a substituted phenyl group, a naphthyl radical, a substituted naphthyl group, a pyridyl radical, a furyl radical or a thienyl radical, R.sup.2 is a hydrogen atom, an alkyl group, a phenyl radical or a substituted phenyl group, R.sup.3 and R.sup.4 are the same or different independently, each being a phenyl radical, or an aralkyl group, or R.sup.3 may form a substituted or non-substituted C.sub.5-6 saturated heterocyclic ring together with R.sup.4 and a possible nitrogen or oxygen atom, R.sup.5 forms a substituted or non-substituted saturated heterocyclic ring together with R.sup.6 and a possible nitrogen or oxygen atom, R.sup.7 is a nitroxy radical or a heteroaryl group, .sub.m and .sub.n are an integer of 2 to 5, Q is a hydrogen atom or ##STR3## in which R.sup.8 and R.sup.9 are the same or different independently, each being a substituted or non-substituted alkyl group, or R.sup.8 may form a substituted or non-substituted C.sub.5-6 saturated heterocyclic ring together with R.sup.9 and a possible nitrogen or oxygen atom, .sub.r is an integer of 2 to 5, T and X are the same or different independently, each being a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or an alkylmercapto group, and Z is an oxygen or sulfur atom. The derivatives and salts thereof are useful for the treatment of complications of diabetes and circulatory diseases.

Hydantoin derivatives for treating complications of diabetes and

Hydantoin derivatives of the formula ##STR1## wherein Ra and Rb are same or different, each being hydrogen atom, alkanoyl, substituted or none-substituted aroyl, heteroaroyl, alkoxycarbonyl, substituted or none-substituted aralkoxycarbonyl, aryloxycarbonyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, substituted or none-substituted N-aralkylcarbamoyl, alkoxyalkyl, 1-(acyloxy)-alkyl, alkylmercapto, substituted or none-substituted arylmercapto, alkylsulfinyl, substituted or none-substituted arylsulfinyl, alkylsulfonyl or substituted or none-substituted arylsulfonyl, but both of Ra and Rb do not concurrently mean hydrogen atom, a process for the preparation of the derivatives, and use thereof as an agent for preventing and curing chronic complications due to diabetes.

(D)-6-fluoro-2,3-dihydro-2',5-dioxo-spiro[4H-1-benzo

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivatives, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,

Process for preparing optically active hydantoins

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group,

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group,

1,4-Dihydropyridine derivatives represented by the formula ##STR1## wherein one of R.sup.1 and R.sup.2 is cycloalkylmethyl group and the other is a group of ##STR2## in which R.sup.3 is hydrogen atom or lower alkyl group and R.sup.4 is hydrogen atom, hydroxyl radical, carboxyl radical, alkoxycarbonyl group, carbamoyl radical, phenyl radical, substituted phenyl radical or trialkylsilyl group, or R.sup.3 and R.sup.4 may be bonded each other, and n and m are an integer of 1 to 6, respectively salts thereof, a process for the preparation of same as well as a pharmaceutical agent comprising the compound or salt, as an effective ingredient.

1,4-dihydropyridine derivatives

A spiro-3-heteroazolidine compound and agents comprising that compound which have special utility as an antidiabetic composition and as a substance to inhibit aldose reductase enzyme activity.

Antidiabetic spiro-3-heteroazolidines

Growing community of inventors

Gifu, Japan

Toshinao Usui